SCHEMBL16619651

SCHEMBL16619651

CNC(=O)OCc1cncc(C(C)(C)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.37
TOP2A P11388 4/20 0.37
TOP2B Q02880 4/20 0.37
CYP11B2 P19099 4/20 0.35
TRPV1 Q8NER1 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 1/20 0.34
CYP11B1 P15538 2/20 0.33
KDM4E B2RXH2 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
NR2F2 P24468 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22364183 0.78 KDM4E (0.41) TOP2ATOP2BSMN1; SMN2L3MBTL1MAPT
SCHEMBL17986606 0.74 KDM4E (0.49) TOP2ATOP2BSMN1; SMN2ALDH1A1LMNA
SCHEMBL16619248 0.73 CYP11B2 (0.38) CYP11B2CYP11B1
SCHEMBL31322592 0.72 CYP11B2 (0.35) CYP11B2CYP11B1
SCHEMBL16619649 0.71 CYP11B2 (0.36) CYP11B2LMNACYP11B1
SCHEMBL31322834 0.71 CYP11B2 (0.40) CYP11B2CYP11B1
SCHEMBL19407165 0.71 CYP11B2 (0.40) CYP11B2CYP11B1
SCHEMBL3508588 0.71 CYP11B2 (0.34) CYP11B2CYP11B1
SCHEMBL836643 0.70 KMT2A (0.58) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL17986556 0.69 PTK2 (0.45) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 P2RX7 353/4885TOP2A 2792/4885TOP2B 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.